Pharmacy Chains vs. Dispensaries: Cannabis Retail by 2032
Photo by hosnysalah via Pixabay.
Picture two counters, maybe a mile apart. One is a Curaleaf location with forty strains of flower behind glass and a budtender walking a customer through terpene profiles. The other is a CVS pharmacy-only format store where a pharmacist hands over a dronabinol prescription, billed through insurance, next to the metformin and the blood pressure meds. As of October 4, 2026, marijuana is still a Schedule I substance under federal law -- full stop, no asterisk. But a narrower and much less discussed move already happened in April 2026: an order shifted FDA-approved THC products and state-licensed medical marijuana onto a Schedule III footing, a pathway that exists alongside, not instead of, the broader rescheduling fight still grinding through DEA administrative proceedings.
That split is the real story here, and it's a quieter one than the headlines about CVS selling pre-rolls suggest, because that's not what's happening. What's actually unfolding is a bifurcation: the molecule -- GMP-grade, dosed, pharmaceutical-grade cannabinoid compounds -- is heading toward pharmacy counters, while flower and edibles stay exactly where they've been, locked inside state-licensed dispensary systems that have no federal approval pathway available to them. This isn't a hypothetical. Kazmira Pharmacy opened in Denver in January 2026 as a licensed compounding pharmacy. Germany's pharmacy-dispensed cannabis market has seen flower prices fall by nearly half in little over a year. The NHS dispensed over 1.7 million cannabis items through English community pharmacies in 2025 alone. And CVS and Walgreens, after years of shrinking their store counts, are both quietly expanding again in 2026. None of these facts alone proves pharmacy chains will remake cannabis retail by 2032 -- but together they sketch a direction worth taking seriously, with the usual caveats about what still has to happen first.
Where Rescheduling Actually Stands Right Now
Photo via Pexels.
Start with what's actually true, not what's trending on social media. As of October 4, 2026, cannabis remains a Schedule I controlled substance federally -- the same classification as heroin, legally speaking, with no accepted medical use and high abuse potential on paper, however disconnected that is from clinical reality. The broader rescheduling proceeding that would move marijuana to Schedule III across the board is not resolved. DEA chief administrative law judge Derek C. Julius stayed that proceeding to weigh whether a newly released GAO report should be entered into the record, with responses from parties due October 13, 2026. That's a procedural pause, not a rejection -- but it means the timeline that industry groups spent the past couple of years projecting has already slipped at least once.
Here's the detail that gets lost in most coverage of the stay: it doesn't touch the April 2026 order. That order already moved FDA-approved marijuana products and state-licensed medical marijuana programs to Schedule III, as a narrower and separate action from the general rescheduling docket. So there are, right now, two tracks moving at different speeds -- one stalled pending a procedural review, one already in effect for a specific slice of the market. That's an unusual regulatory structure, but it's the one we have.
Why does a specific date -- November 6, 2026 -- matter at all here? DEA hearing procedure requires that any final order can't take effect until at least 55 days after the administrative law judge's recommended decision is formally served on the parties. Count backward from December 31, and you land on roughly November 6 as the last plausible date a recommendation could be issued and still produce a 2026 effective date for the broader rescheduling. Miss that window and the clock resets into the following year at earliest, pending how quickly the judge moves after the GAO report dispute resolves.
This isn't just a procedural curiosity. The broader rescheduling timeline is directly tied to 280E tax relief eligibility for adult-use cannabis operators -- the IRS provision that currently bars businesses trafficking in Schedule I substances from deducting ordinary business expenses, which can push effective tax rates on cannabis retailers well above those of any other retail category. Whether and when that relief arrives is a genuine competitive variable for dispensaries facing pharmacy-channel competition, a point worth holding onto through the rest of this piece.
The Split That's Coming: Molecule vs. Flower
Photo via Pexels.
Industry analysts tracking the pharmaceutical cannabinoid space have converged on a rough estimate: something like a three-year window before large pharmacy chains become a visible, meaningful dispensing channel for FDA-approved or federally compliant THC medicines. That's a projection, not a certainty, and it rests on assumptions about reimbursement and manufacturing scale that haven't fully played out. But the groundwork is already there in named, existing products.
AbbVie's Marinol and other dronabinol formulations are the clearest example -- synthetic THC, FDA-approved, but cleared only for chemotherapy-induced nausea and AIDS-related wasting syndrome. Not general medical use, and certainly not recreational use. That narrowness is the whole point: this is a pharmaceutical product moving through a pharmaceutical approval process, with all the clinical trial requirements and indication-specific labeling that implies. Meanwhile, companies like Benuvia already manufacture GMP-grade cannabinoid material at real scale, feeding compounding pharmacies that convert it into prescription-ready formulations. The supply chain for the molecule lane isn't a future hypothetical -- it exists today, at commercial volume.
What this doesn't mean is a single merged cannabis market where pharmacies and dispensaries compete head-to-head on the same shelf. Flower and edibles stay in state-regulated dispensary systems because there's no federal approval pathway that covers smoked or vaped plant material -- the FDA's drug approval framework is built around standardized dosing and delivery, which combustible flower structurally can't satisfy in its current form. Whole-plant cannabis extract products face a steeper, slower approval road than isolated or synthesized cannabinoids, and nothing in the April 2026 order changes that.
The honest counter-case here matters more than the scheduling news itself: reimbursement, not scheduling, is the actual bottleneck. Schedule III status makes it legally easier to research, manufacture, and prescribe these compounds -- it does nothing to guarantee an insurer or Medicare/Medicaid program will cover them. Without that coverage decision, pharmacy-dispensed THC remains a cash-pay niche serving patients with specific FDA-labeled indications, however convenient the pharmacy counter becomes. Scale requires both legal clearance and a payer willing to write the check, and only one of those two things has happened so far.
Kazmira and the Compounding Pharmacy Blueprint
Photo by National Cancer Institute via Unsplash.
If you want a working model of how this expansion actually happens on the ground, rather than in a DEA filing, look at Kazmira Pharmacy's launch in Denver in January 2026. It opened as the first licensed 503A compounding pharmacy offering THC-free, prescription-only CBD -- a narrower product than the full THC conversation this piece is mostly about, but a structurally important first move. Compounding pharmacies operate under state pharmacy board oversight rather than the full FDA retail drug approval apparatus, which makes 503A status a genuinely faster on-ramp than waiting for federal scheduling clarity to fully resolve.
Kazmira isn't staying put in Colorado. The company has been working directly with state pharmacy boards with an explicit goal of expanding into 20 or more additional states during 2026, including Arizona, Florida, Texas, and Utah -- a list that spans both traditionally cannabis-friendly and traditionally conservative regulatory environments, which suggests the compounding-pharmacy angle sidesteps some of the political friction that full-scale dispensary licensing runs into.
This is the part worth sitting with: 503A compounding status is a much narrower, state-board-regulated lane than a full retail pharmacy chain rollout would be. It doesn't require the same federal sign-off, doesn't require building out a dispensary-style retail operation, and doesn't require resolving the Schedule I/Schedule III question for THC specifically. That's precisely why it's moving faster than the CVS-and-Walgreens conversation -- it's a lower-risk, lower-regulatory-friction entry point that larger chains could plausibly license or replicate rather than build from scratch.
But notice what Kazmira is not doing yet: it launched THC-free. That's a deliberate hedge, not an oversight, and it tells you something important about how cautious even the most aggressive pharmacy-adjacent operators are being around Schedule I THC specifically. For a Kazmira-style compounding model to carry actual THC rather than CBD, the April 2026 order's state-medical-license pathway would need much broader buy-in from individual state pharmacy boards -- DEA rescheduling alone doesn't automatically authorize a state board to approve THC compounding; that's a separate, state-by-state administrative lift that hasn't happened yet.
The European Preview: Germany and the NHS
NHS community pharmacy dispensing of cannabis items surged from about 670,000 to over 1.7 million in the space of a year, more than doubling.
The United States isn't the first place to route cannabis through pharmacy infrastructure -- Germany and the UK got there first, and both offer a genuinely useful preview of what happens once that door opens, even if neither maps perfectly onto the US system.
In Germany, pharmacy-dispensed medical cannabis flower prices fell 46%, down to €4.52 a gram, over the 14 months ending in March 2026. That's not a small price movement -- it's the signature of a market moving from scarcity pricing toward genuine supply-side competition, the same pattern you'd expect to see as more cultivators and distributors get licensed and pharmacies get comfortable stocking and billing for the product. A pharmacy-based medical cannabis market that started cautiously has matured enough in a little over a year to meaningfully compress margins.
The NHS data points the same direction, faster. English community pharmacies dispensed 1,701,064 cannabis items in 2025, up 154% year-over-year. That's not incremental growth -- that's a system that found its footing and then scaled rapidly, which is exactly what you'd predict once legal pharmacy-dispensing frameworks, insurance billing relationships, and cold-chain compliance systems are already in place and just need a new product category routed through them. Pharmacies didn't have to build dispensing infrastructure from the ground up the way American cannabis dispensaries did, since many had already been built out for years prior -- they already had it, and cannabis is simply the newest thing moving through existing plumbing.
Two caveats keep this from being a clean 1:1 forecast for the US. First, Germany and the UK dispense cannabis flower itself through pharmacies, under national health frameworks -- the US pharmaceutical THC pathway opened by the April 2026 order is narrower by design, covering FDA-approved formulations like dronabinol, not flower. Second, and more important: the NHS and Germany's statutory health insurance system are single-payer or near-single-payer structures. A 154% single-year growth rate reflects a unified system flipping a switch, not the fragmented, state-by-state, insurer-by-insurer patchwork the US operates under. Expect the US growth curve, if it materializes, to be slower and lumpier -- state pharmacy board approvals, individual insurer reimbursement decisions, and DEA scheduling status all have to line up independently, and they rarely move in sync.
CVS, Walgreens, and the Footprint Question
Photo via Pexels.
Set the scheduling debate aside for a moment and look at real estate, because that's often where corporate strategy shows up before the press releases do. CVS is planning to grow its store count again in 2026, expecting to open around 60 new locations, including nearly 20 smaller pharmacy-only sites -- a real reversal after a multi-year stretch of store closures that had analysts treating CVS's retail footprint as a shrinking, not growing, asset. Walgreens, now under private equity ownership following last year's acquisition, is planning to slow the pace of its own closures in 2026 as well. Neither chain has announced anything resembling a cannabinoid dispensing strategy tied to this expansion -- this is a factual observation about footprint, not a confirmed business plan.
It's worth a gut-check against history before reading too much into that footprint shift. CVS and Walgreens both rolled out CBD topicals into somewhere between 800 and 1,500 stores in the first wave of hemp-derived CBD legalization following federal hemp legislation. Those were low-THC wellness products -- lotions and balms, not prescriptions -- and that rollout tells you about a past wellness-retail trend, not a current cannabinoid pharmaceutical strategy. It's useful history precisely because it shows these chains move fast on cannabinoid products once the legal ambiguity clears, but it's not itself evidence of what's coming next.
What renewed footprint growth plausibly signals is more structural: these smaller-format, pharmacy-only stores are a format that could add a pharmaceutical cannabinoid dispensing counter -- think dronabinol-type prescriptions -- without the real estate footprint or state dispensary licensing complexity a full retail cannabis buildout would require. A pharmacy counter is already a pharmacy counter; adding a new FDA-approved molecule to the formulary is a fundamentally smaller lift than opening a licensed dispensary from zero.
The realistic 2032 scenario isn't CVS turning into a dispensary chain. It's CVS and Walgreens becoming a parallel channel specifically for pharmaceutical-grade, insurance-billable THC prescriptions -- overlapping with, but not replacing, the existing dispensary operators who handle flower and edibles: Curaleaf at roughly 145 stores across 23 states, Trulieve at around 190 stores, RISE at about 90, and Zen Leaf's growing regional footprint. Two channels, serving overlapping but distinct customer needs, is the more defensible forecast than any single-winner story.
What This Means for Dispensary Chains Through 2032
If this split plays out the way the evidence so far suggests, dispensary chains don't lose their whole market -- they lose a specific slice of it first, and it's worth naming which slice. Patients using cannabis for nausea, chemotherapy side effects, AIDS-related wasting, or other conditions that already have an FDA-approved indication are the ones most likely to migrate toward insurance-reimbursed pharmacy THC once that reimbursement question gets resolved. That's a direct echo of how mail-order pharmacy and pharmacy benefit manager competition reshaped independent drugstores over the past two decades -- the chronic, recurring, insurance-covered prescriptions moved to the lowest-friction, lowest-cost channel first, while specialty and immediate-need business stayed local.
What doesn't migrate, at least under any currently visible federal pathway, is flower, edibles, and the broader adult-use and recreational experience market. There's no FDA approval mechanism in place or in progress that covers smoked or vaped plant material, and nothing in the April 2026 order changes that fact. That business stays with Curaleaf, Trulieve, RISE, and similar state-licensed operators, essentially by default rather than by competitive victory.
Layer the 280E question back in here, because it's a separate lever from scheduling status and it cuts in the dispensaries' favor if it resolves. If the stayed broader rescheduling proceeding eventually clears and marijuana moves fully off Schedule I, state-licensed adult-use retailers gain a real cost-structure advantage -- full deductibility of ordinary business expenses -- that pharmacy-channel competitors don't need in the first place, since they're not operating in Schedule I territory to begin with. That's a case where resolving the federal question helps the incumbent dispensary chains close a gap rather than widen one.
So the bull case for dispensaries: they retain the experiential, product-variety, and recreational customer base that pharmacies have no FDA-approved pathway to touch, and 280E relief -- if and when it arrives -- narrows their structural cost disadvantage against better-capitalized pharmacy chains. The bear case: if dronabinol-type reimbursement does arrive at pharmacy counters, and pharmacy chains can undercut on medical-use pricing the way Germany's €4.52-a-gram pharmacy market shows is achievable once supply and distribution mature, dispensaries could see real erosion in medical-card patient volume even while their recreational volume holds steady or grows. Both outcomes are plausible from where things stand in October 2026 -- which one dominates depends on reimbursement decisions that haven't been made yet.
Strip away the scheduling jargon and the 2032 map that's taking shape looks less like a winner-take-all contest and more like two lanes running in parallel. Pharmacy chains -- CVS, Walgreens, and the compounding-pharmacy networks modeled on Kazmira -- plausibly end up controlling the reimbursed, FDA-cleared cannabinoid molecule business: dronabinol-type prescriptions, billed through insurance, dispensed alongside everything else in the pharmacy formulary. State-licensed dispensary chains keep flower, edibles, and the recreational and experiential side of the market, because no federal approval pathway currently reaches smoked or vaped plant material, and nothing on the current DEA docket suggests that's about to change.
The pace of all this hinges on two variables worth tracking specifically, rather than on scheduling status as a single headline. First: when, or if, the stayed DEA rescheduling proceeding resumes after the GAO report dispute resolves, and whether a recommended decision lands in time to matter for the November 6 window or slides later. Second, and arguably more decisive: whether insurers actually start reimbursing dronabinol-type prescriptions at the pharmacy counter. Scheduling status opens legal doors; reimbursement decisions are what determine whether anyone walks through them at scale.
Dispensary operators who treat this whole conversation as a distant hypothetical, something to worry about closer to 2030, are misreading the two best pieces of evidence available right now. Kazmira went from a single Denver compounding pharmacy to targeting 20-plus states within the same calendar year. The NHS saw pharmacy-dispensed cannabis volume jump 154% in a single year once the dispensing framework was in place. Pharmacy infrastructure -- the licensing relationships, the insurance billing systems, the cold-chain compliance already built for a thousand other drug categories -- scales fast once the legal door opens even slightly. The smart move for dispensary operators isn't to wait and see; it's to double down now on exactly what pharmacies have no plausible path to replicate: flower variety, the sensory and recreational consumption experience, and the kind of product knowledge a trained budtender provides that a pharmacist filling a standardized prescription simply isn't positioned to offer.
